ANGPTL3 Inhibitors Market Size, Share & Industry Analysis, By Product (Evinacumab and Others), By Disease Indication (Homozygous Familial Hypercholesterolemia (HoFH) and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global ANGPTL3 inhibitors market size was valued at USD 158.1 million in 2024 and is projected to reach USD 1,252.1 million by 2032, exhibiting a CAGR of 32.4% during the forecast period. The market is projected to grow exponentially in the upcoming years due to the higher efficiency of the innovative technology, along with increasing emphasis on research and development.

ANGPTL3 inhibitor plays a crucial role in regulating lipid metabolism. These ANGPTL3 inhibitor drugs showcase higher efficiency as they follow the LDL receptor–independent lipid pathway. These make them an effective drug class against patients who have genetic cholesterol problems. Due to these factors, the market is poised for significant growth in the near future. Owing to this high growth potential of the market, several key companies are focusing on the development of their pipeline candidates.

• For instance, in June 2025, CRISPR Therapeutics updated results across its in vivo cardiovascular disease programs. These included new data for CTX310, targeting ANGPTL3, from an ongoing Phase 1 clinical trial, reinforcing the potential to transform the treatment of serious cardiovascular diseases.

Furthermore, strategic activities such as increased research and development, collaborations, mergers, and acquisitions of key companies are anticipated to drive the growth of the market in the forthcoming years.

ANGPTL3 Inhibitors Market Driver

Rising Prevalence of Cardiovascular sand Lipid Disorders to Drive Market Growth

The increasing number of individuals suffering from cardiovascular diseases and lipid disorders is a major factor driving the growth of the ANGPTL3 inhibitors market. Due to sedentary lifestyles, poor dietary habits, and rising obesity rates have led to higher cholesterol and triglyceride levels which has been observed globally. These factors have led to an increasing demand for novel innovations to manage complex lipid abnormalities. This rising disease burden and unmet medical need are expected to significantly boost the adoption of these therapies in the coming years.

• For instance, in May 2024, the Centers for Disease Prevention and Control (CDC) reported that about 86.0 million U.S. adults aged 20 or older had total cholesterol levels above 200 mg/dL. Such a high prevalence highlighted the need for newer, more effective therapies and drove the market growth.

Download Free sample to learn more about this report.

According to data published by the CDC in October 2024, the prevalence of high total cholesterol (240 mg/dL or more) among adults aged 20 and older in the U.S. varies by race and ethnicity, with non-Hispanic Asian male adults with the highest risk.

ANGPTL3 Inhibitors Market Restraint

Safety Concerns to Restrain Market Growth Potential

Safety concerns such as potential effects on liver function, fat accumulation, and long-term tolerability pose challenges for the regulatory approval and clinical adoption of these drugs. Moreover, the complex molecular design of antisense and RNA-based therapies increases the risk of off-target effects and adds to the development time and cost. These factors collectively create uncertainty in the clinical success rate and delay the broader availability of ANGPTL3 inhibitors in the market.

• For example, in January 2022, Pfizer Inc., in collaboration with Ionis Pharmaceuticals, Inc., discontinued the clinical development program for vupanorsen (PF-07285557) for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). As the magnitude of non-HDL-C and TG reduction observed did not support continuation of the clinical development program for CV risk reduction or SHTG, and was associated with an increase in liver fat, elevated liver enzymes, the clinical trial was discontinued.

Such factors are likely to hamper the development of these innovative therapies.

ANGPTL3 Inhibitors Market Opportunity

Expanding Therapeutic Applications and Advancements in RNA and Gene Editing Technologies to Create Growth Opportunities

The ANGPTL3 inhibitors market is poised for significant growth driven by expanding research initiatives and ongoing innovation for expanding therapeutic scope. The ability of ANGPTL3 inhibitors to target multiple lipid parameters positions them for use beyond rare genetic disorders, including mixed hyperlipidemia, hypertriglyceridemia, and residual cardiovascular risk. As clinical data continue to validate their safety and durability, the market is expected to witness strong growth opportunities through expanded indications and next-generation delivery technologies.

• For instance, in May 2024, Arrowhead Pharmaceuticals, Inc. showcased positive results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Such factors offer new growth avenues to the global market of ANGPLT3 inhibitors.

Segmentation

Key Insights

The report covers the following key insights:

• Epidemiology of Homozygous Familial Hypercholesterolemia (HoFH), By Key Countries, 2024
• Reimbursement Scenarios, By Key Countries/ Regions
• Key Industry developments (Mergers, Acquisitions, Partnerships, and Others)
• Pipeline Analysis, By Key Companies
• Overview: Therapeutic Alternatives in the Market

Analysis by Product

On the basis of product, the global ANGPTL3 Inhibitors market is segmented into Evinacumab and others.

The Evinacumab segment is expected to hold a leading market share as it is the only U.S. FDA-approved ANGPLT3 inhibitor. Its approval for the treatment of Homozygous Familial Hypercholesterolemia (HoFH) gives it a clear commercial and clinical advantage over pipeline candidates still in development. The drug’s proven ability to significantly reduce LDL cholesterol levels, even in patients unresponsive to standard therapies, has established its strong market presence. Additionally, its regulatory approval and expanding label for pediatric use further strengthen its leadership position in the global ANGPTL3 inhibitors market.

• For Instance, in September 2025, Regeneron Pharmaceuticals, Inc. received approval from the U.S. FDA for Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of children from age 1 to less than 5 years old with HoFH. Such developments are expected to lead the segment growth.

Analysis by Disease Indication

Based on disease indication, the market is segmented into Homozygous Familial Hypercholesterolemia (HoFH) and others.

Among these, the Homozygous Familial Hypercholesterolemia (HoFH) segment is expected to dominate the global ANGPTL3 Inhibitors market. The segment’s dominance is due to high unmet medical need with limited effective treatment options. Patients with this rare genetic disorder experienced extremely high LDL cholesterol levels from birth, often unresponsive to conventional lipid-lowering therapies. ANGPTL3 inhibitors bridge the gap with current therapies and showcase high efficacy.

• For instance, in March 2025, PubMed published a study titled ‘High burden of disease in patients with homozygous Familial Hypercholesterolemia despite recent advances in therapies and updated guidelines: A real-world study’ reported that patients with HoFH are undertreated, resulting in suboptimal control of LDL-C levels and a high prevalence of ASCVD.

Analysis by Distribution Channel

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

Among these, the hospital pharmacies segment is anticipated to hold a significant segmental share. These drugs are administered under medical supervision, often through intravenous infusion in controlled healthcare settings. Moreover, most initial prescriptions and follow-up treatments for rare genetic disorders such as HoFH are managed by specialists within hospital-based programs, further reinforcing hospital pharmacies as the leading distribution channel for ANGPTL3 inhibitors. In addition, collaborations among key operational entities and hospitals to optimize the distribution of these novel therapies drive the segmental growth.

• For instance, in December 2024, Ultragenyx Pharmaceutical Inc., in collaboration with NHS England, implemented the commissioning of Evkeeza (evinacumab) following the National Institute for Health and Care Excellence (NICE) final guidance in September. The collaboration enabled the routinely commission of Evkeeza by NHS England and was made available in seven hospital trusts in England. Such developments are expected to drive the segmental growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of region, the market has been analyzed across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

North America accounted for around 60% share of the global ANGPTL3 Inhibitors market in 2024. The dominance of the region is due to its strong healthcare infrastructure, early adoption of innovative biologic therapies, and rising prevalence of lipid disorders. Additionally, higher healthcare spending and better reimbursement frameworks encourage wider patient access, making North America the leading and fastest-growing market for ANGPTL3 inhibitors.

• For instance, in January 2024, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued a recommendation for public-plan reimbursement of Evkeeza as an adjunct therapy in patients aged 5 years and older with Homozygous Familial Hypercholesterolemia (HoFH), under certain conditions. Such reimbursement initiatives are anticipated to drive growth in the region.

Europe is expected to grow at a significant CAGR over the forecast period due to the growing prevalence of lipid disorders, along with rising awareness of rare lipid-genetic diseases in the region. These factors contribute to a large patient pool in the region to increase the demand. Further, approval by regulatory bodies in the region is expected to drive the growth in the region.

• For instance, in December 2023, Ultragenyx Pharmaceutical Inc. received extended approval from the European Commission (EC) for Evkeeza (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH).

The Asia Pacific market is expected to grow at a stable CAGR during the forecast period. The region is anticipated to witness growth due to improved access to advanced therapies and enabling more treatments for lipid disorders. Additionally, expanding clinical trials and government approvals to drive growth in the region. Together, these factors are supporting a favorable environment for ANGPTL3-targeted drugs in the Asia Pacific region.

• For instance, in September 2024, Jiangsu Hengrui Pharmaceuticals Co. received Breakthrough Therapy Designation (BTD) from China’s Center for Drug Evaluation (CDE) for its drug candidate ANGPTL3 Inhibitor SHR-1918. This monoclonal antibody (mAb) targeting angiopoietin-like protein 3 (ANGPTL3) was intended for the treatment of homozygous familial hypercholesterolemia (HoFH).

Key Players covered

The global ANGPTL3 inhibitors market is consolidated, with a few players capturing a major market player. The report includes the profiles of the following key players.

• Regeneron Pharmaceuticals Inc (U.S.)
• Arrowhead Pharmaceuticals, Inc. (U.S.)
• Eli Lilly (U.S.)
• Ultragenyx Pharmaceutical Inc. (U.S.)
• CRISPR Therapeutics. (Switzerland)

Key Industry Developments

• September 2025: Argo Biopharmaceutical Co., Ltd., collaborated with Novartis AG for multiple cardiovascular assets in the company’s pipeline. This collaboration granted Novartis the right to license ex-China rights to two discovery-stage next-generation molecules for the treatment of severe hypertriglyceridemia (sHTG) and mixed dyslipidemia, following a combination trial conducted by Argo.
• July 2025: Eli Lilly and Company acquired Verve Therapeutics, Inc., to develop innovative genetic medicines for cardio-metabolic disease.